Nemaura Medical Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Ghadar-Ghadr Arash, was filed 09 Jan 2024.
Nemaura Medical Inc.: what insiders have been doing
Nemaura Medical Inc. has a thin disclosure history in our data (latest filing: 9 January 2024). New filings will appear here as soon as they are published. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Since the insiders bought
- -99.9%Entry US$0.08 · Close at T+365 US$0.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended March 2023 · cache
- 100,000 shares@ US$0.14100.0% of flowCommon StockSEC:0001079973-24-000047:0Canonical exit: 4 Apr 2024 (T+90)
- 22,293 shares0Common StockSEC:0001079973-22-000115:0
- 87,537,000 shares0Common StockSEC:0001140361-18-027707:0
- 22,705,000 shares0Common StockSEC:0001140361-18-027710:0
- 27,082,000 shares0Common StockSEC:0001140361-18-027711:0
- 27,082,000 shares0Common StockSEC:0001140361-18-027410:0
- 87,537,000 shares0Common StockSEC:0001140361-18-027408:0
- 22,705,000 shares0Common StockSEC:0001140361-18-027409:0
8 of 8 declarations
About Nemaura Medical Inc.
Nemaura Medical Inc. is a U.S.-listed medical technology company quoted on NASDAQ, operating from the United States and positioned at the intersection of medical devices, metabolic monitoring and digital health. According to the company’s own materials, Nemaura was founded in 2011 and originally developed a non-invasive microsystem platform designed to measure biological markers at the skin surface. Over time, it broadened its strategy from core sensing technology toward wearable products and software-enabled healthcare solutions aimed at chronic disease management. ([nemauramedical.com](https://nemauramedical.com/?utm_source=openai))
The company’s business model is centered on its BEAT® technology platform, which supports several product and service lines. The best-known offering is sugarBEAT®, a non-invasive continuous glucose monitoring solution marketed as a flexible alternative to traditional invasive glucose tracking. Nemaura also promotes BEAT®diabetes, a digital diabetes and prediabetes management program, and Miboko, a broader metabolic health and weight-management concept built around glucose insight and lifestyle support. In addition, the company references development efforts in continuous lactate monitoring and temperature monitoring, with both medical and non-medical use cases. ([nemauramedical.com](https://nemauramedical.com/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Nemaura’s differentiator is its non-invasive approach and its attempt to combine sensors, AI, and digital care pathways into one ecosystem. That gives the company a distinct profile versus larger, better-capitalized diabetes technology players that dominate the continuous glucose monitoring market. At the same time, Nemaura remains a niche and early-stage commercial story, with execution risk tied to regulatory progress, product adoption, manufacturing scale-up and the ability to convert scientific promise into recurring revenue. ([nemauramedical.com](https://nemauramedical.com/about-us/?utm_source=openai))
Geographically, the company presents itself as internationally oriented, with commercial ambitions in the United States and Europe. Its corporate narrative emphasizes that the platform evolved from work developed in 2011 into a broader connected-health offering. For investors, this matters because the equity story is still largely driven by commercialization milestones rather than mature operating scale. The company’s small-cap profile means liquidity, capital needs and milestone delivery remain important factors to watch. ([nemauramedical.com](https://nemauramedical.com/?utm_source=openai))
Recent notable developments include continued company messaging around its digital healthcare initiatives and the ongoing visibility of SEC disclosure activity, including Form 4 insider transactions that place the stock on investors’ radar. Overall, Nemaura Medical Inc. on NASDAQ is best viewed as an innovative but speculative health-tech name: the upside case depends on commercial traction for its non-invasive monitoring platform and related digital programs, while the risk profile remains elevated due to the early-stage nature of the business. ([nemauramedical.com](https://nemauramedical.com/?utm_source=openai))
